Cancure
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • Public Documents
    • News
  • Contact
  • Search

Servier, Pieris launch up to $1.8B immuno-oncology alliance

January 5, 2017
Servier will partner with Pieris Pharmaceuticals to co-develop…

News

  • NousCom receives $49M to trial off-the-shelf cancer vaccine November 9, 2017
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans November 1, 2017
  • Incyte pays MacroGenics $150M for PD-1 inhibitor October 26, 2017
  • Gilead buys CAR-T developer Kite Pharma for $12B August 29, 2017

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2015 All rights reserved.
Scroll to top